CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Faron reports 85% response rate in frontline higher-risk MDS trial of bexmarilimab combination

By Public Technologies
  • Faron Pharmaceuticals will present five abstracts on bexmarilimab, Clever-1 biology and higher-risk MDS at ASH in New Orleans, December 12-15, 2026.
  • BEXMAB survival outcomes varied by TP53 mutation status, with the longest survival observed in previously treated patients without TP53 mutations.
  • Previously reported frontline results showed remissions with bexmarilimab combined with azacitidine; its safety profile appeared comparable to azacitidine alone.
  • The randomized Phase 2b BEXERA trial targets approximately 90 previously untreated patients to select a bexmarilimab dose for Phase 3 development.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faron Pharmaceuticals Oyj published the original content used to generate this news brief on November 04, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk